This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eric T. Choi, MD; Allan D. Callow, MD, PhD; Niraj L. Sehgal; David M. Brown, MD; Una S. Ryan, PhD

Arch Surg. 1995;130(3):257-261.

Abstract
Objective
To determine if halofuginone hydrobromide, a specific type I collagen inhibitor, could prevent intimal hyperplasia at a vascular anastomosis.

Design
Intimal hyperplasia is characterized by smooth muscle cell proliferation and extracellular matrix accumulation. Halofuginone was used to block collagen production and smooth muscle cell proliferation in cell cultures and in a rabbit model of an end-to-end anastomosis of the right common carotid artery. Animals were fed a nontoxic dose of halofuginone. Eighteen rabbits were fed the inhibitor in a randomized blinded fashion and were examined after 4 weeks by harvesting the arteries after perfusion fixation at physiologic pressures.

Results
Halofuginone inhibited smooth muscle cell proliferation in vitro and had no effect on cell viability. Morphometric quantification verified that halofuginone treatment significantly attenuated anastomotic intimal thickness.

Conclusion
Oral administration of halofuginone inhibits intimal hyperplasia at vascular anastomoses. Intimal hyperplasia inhibition by halofuginone may be a therapeutic option for preventing arterial stenosis in vascular surgery.

(Arch Surg. 1995;130:257-261)

Author Affiliations
From the Department of Surgery (Drs Choi and Brown), Washington University School of Medicine (Mr Sehgal), St Louis, Mo, and the Section of Vascular Surgery, the Department of Surgery (Dr Callow), and the Department of Medicine (Dr Ryan), Boston (Mass) University School of Medicine.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy
McLoon
Am. J. Physiol. Heart Circ. Physiol. 2008;294:H1505-H1507.
FULL TEXT  

A Model of Primary Atherosclerosis and Post-Angioplasty Restenosis in Mice
Leidenfrost et al.
Am. J. Pathol. 2003;163:773-778.
ABSTRACT | FULL TEXT  

Analysis of the effect of halofuginone on bleomycin-induced scleroderma
Yamamoto and Nishioka
Rheumatology (Oxford) 2002;41:594-596.
FULL TEXT  

Inhibition of Matrix Metalloproteinase-2 Expression and Bladder Carcinoma Metastasis by Halofuginone
Elkin et al.
Clin. Cancer Res. 1999;5:1982-1988.
ABSTRACT | FULL TEXT  

Inhibition of Collagen Synthesis, Smooth Muscle Cell Proliferation, and Injury-Induced Intimal Hyperplasia by Halofuginone
Nagler et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:194-202.
ABSTRACT | FULL TEXT